{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Industrial Aid[C45678]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT00790140: Phase 4 Interventional Unknown status Esophageal Cancer
(2005)
Source URL:
First approved in 1984
Source:
NeuroBion by BENARD INDUSTRIES INC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 1984
Source:
Hemocyte F by US Pharmaceutical Corporation
Source URL:
Class:
POLYMER
Hypromellose is a semisynthetic, inert, viscoelastic methyl and hydroxypropyl mixed ether of cellulose used as eye drops, as well as an excipient and controlled-delivery component in oral medicaments, found in a variety of commercial products. Hypromellose is considered an inert substance as it has no direct pharmacological activity. The viscosity promoting properties of hypromellose prolong the retention time and improve adhesion of synthetic tears to the cornea and conjunctiva. As a result, the tear film breakdown time is prolonged and/or the tear film stability is enhanced. A stable tear film protects the cornea from dryness Hypromellose is the most commonly used in hydrophilic matrix fabrication. Hypromellose provides the release of a drug in a controlled manner, effectively increasing the duration of release of a drug to prolong its therapeutic effect.
Status:
Possibly Marketed Outside US
Source:
FLUIDBASE AHA 10 by LABORATORIO GENOVE S.A.
(2016)
Source URL:
First approved in 1983
Source:
NDA018861
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2010)
Source URL:
First approved in 1979
Source:
ANDA062129
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
PRENATAL PLUS IRON by Blenheim Pharmacal, Inc.
(2010)
Source URL:
First approved in 1976
Source:
NDA017078
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA020907
(1998)
Source URL:
First approved in 1974
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA090931
(1997)
Source URL:
First approved in 1974
Source:
NDA050813
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA208944
(1968)
Source URL:
First approved in 1968
Source:
NDA208944
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Fem pH by Pharmics, Inc.
(1999)
Source URL:
First approved in 1962
Source:
NDA022259
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2001)
Source URL:
First approved in 1953
Source:
NDA008762
Source URL:
Class:
POLYMER
